Accelerating Breakthrough Discoveries into Medicines

George Trainor, PhD

George Trainor, PhD

George L. Trainor, PhD has 30 years’ experience in the biotechnology and pharmaceutical industries and currently is a strategic scientific consultant to BioMotiv and an industry consultant.

He has expertise in drug discovery strategy development and execution, medicinal chemistry and the application of transformative technologies. Leading teams of more than 100 scientists, he has advanced more than 35 drug candidates into clinical development across a spectrum of therapeutic areas, including antivirals, cancer, neuroscience and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.

Dr. Trainor began his active consulting career after leaving Bristol-Myers Squibb Company as Vice President – Oncology and Early Discovery Chemistry. While there, he was responsible for all aspects of medicinal chemistry for the oncology area as well as hit-to-lead activities in support of all therapeutic areas. Prior to Dupont/Dupont Merck Pharmaceuticals merger with Bristol-Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont, working under Paul Anderson, PhD.

Prior to that position, Dr. Trainor was a scientist in the Dupont Central Research and Development Department. His key contribution was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. In 2011, Dr. Trainor won the American Chemical Society’s “Heroes of Chemistry Award” for his work on DNA sequencing. 

Dr. Trainor holds a bachelor’s degree from Stevens Institute of Technology, Hoboken, NJ and a PhD in organic chemistry from Harvard University, Cambridge, Mass. At Harvard, he studied under Yoshito Kishi, PhD. He served a National Institutes of Health (NIH) postdoctoral fellowship at Columbia University, New York, under Ronald Breslow, PhD.

Dr. Trainor holds nearly 20 patents and has more than 80 peer-reviewed publications to his credit. He has served on grant review study sections for the National Institutes of Health and U.S. Department of Energy.